Parallax Volatility Advisers
FOLD

Parallax Volatility Advisers’s Amicus Therapeutics FOLD Stock Holding History

Parallax Volatility Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-192,200
Closed -$2.89M – 2484
2018
Q1 		$2.89M Sell
192,200
-28,700
-13% -$437K ﹤0.01% 672
2017
Q4 		$3.18M Buy
220,900
+65,300
+42% +$897K ﹤0.01% 763
2017
Q3 		$2.35M Buy
155,600
+115,600
+289% +$1.53M ﹤0.01% 793
2017
Q2 		$403K Hold
40,000
– – ﹤0.01% 1281
2017
Q1 		$285K Buy
+40,000
New +$253K ﹤0.01% 1794

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Parallax Volatility Advisers's FOLD Position: Q2 2025 in Review

Parallax Volatility Advisers sold out of Amicus Therapeutics (FOLD) in Q2 2025, closing a stake of 5,900 shares — an estimated $48.1K sold.

Parallax Volatility Advisers first reported a position in FOLD in Q3 2015 and held it in 11 quarters. The position peaked at $2M in Q3 2017. 272 funds tracked by Wall St. Rank hold FOLD as of Q2 2025.

  • Parallax Volatility Advisers reported no remaining Amicus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,900 Amicus Therapeutics shares in Q2 2025, an estimated $48.1K.
  • Parallax Volatility Advisers first reported a position in Amicus Therapeutics in Q3 2015 and held it in 11 quarters.
  • Parallax Volatility Advisers's Amicus Therapeutics position peaked at $2M in Q3 2017.
  • 272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2025.

Based on Parallax Volatility Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.